Ognomy Sleep
Ognomy Sleep is a Buffalo-based virtual sleep apnea care platform offering telehealth consultations, at-home sleep testing, and longitudinal treatment (CPAP, oral appliances, Inspire, Zepbound) across all 50 US states, serving 25,000+ patients with in-network coverage for 200M+ lives.
- Company typePrivate
- Founded2019
- HeadquartersBuffalo, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Ognomy Sleep does
Ognomy Sleep (Ognomy Inc.) is a private, Buffalo, NY-based virtual sleep apnea care provider founded in 2019 by Dr. Daniel Rifkin, a sleep medicine specialist with 28 years of clinical experience. The company operates an end-to-end telehealth platform that connects patients in all 50 US states with sleep medicine physicians for consultation, at-home sleep testing, diagnosis, and longitudinal treatment management. Its clinical scope spans CPAP therapy (delivered via a Resmed partnership and Pathway program integration), oral appliance therapy, Inspire hypoglossal nerve stimulation for CPAP-intolerant patients, and — most recently — Zepbound (tirzepatide) prescriptions for adults with moderate-to-severe OSA and obesity via Eli Lilly's LillyDirect marketplace. The platform is device-agnostic on the diagnostic side, integrating five FDA-cleared home sleep testing devices (WatchPAT, ApneaLink Air, SleepImage Ring, EnsoData, NightOwl) plus Oura Ring wearable data, with results interpreted by board-certified sleep specialists and digital sleep reports delivered back to referring primary care providers.
The business model blends per-visit telehealth fees ($124 new patient, $99 follow-up), self-pay HST packages ($320), insurance billing across 200M+ in-network lives (including Medicare), and revenue from device coordination, oral appliance, Inspire implant, and Zepbound prescription services. Go-to-market is hybrid: a direct-to-consumer motion driven by SEO, a 90-second online sleep apnea quiz, and a mobile app, paired with a provider-referral channel (PCPs receive a dedicated portal with EMR integration and digital reports) and channel partnerships with Resmed and Eli Lilly's LillyDirect. The company is ACHC-accredited for home sleep testing, HIPAA-compliant, MedTech Breakthrough 'Best Overall SleepTech Solution' (2026), and reports 25,000+ patients treated, 50,000+ platform visits, 4.9/5 average satisfaction, and 74% CPAP adherence versus an industry average of 45%. Capital raised to date totals roughly $17.7M across three rounds, with the most recent $14.9M round closing in May 2026.
Ognomy Sleep firmographics
Firmographics- Name
- Ognomy Sleep
- Legal name
- Ognomy Inc.
- Website
- https://ognomy.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ognomy Sleep is a Buffalo-based virtual sleep apnea care platform offering telehealth consultations, at-home sleep testing, and longitudinal treatment (CPAP, oral appliances, Inspire, Zepbound) across all 50 US states, serving 25,000+ patients with in-network coverage for 200M+ lives.
- Ownership category
- akta.pro rank
Ognomy Sleep industry classification
Industry- Product category
- Telehealth Sleep Medicine
- NAICS
- Offices of Physicians (6211)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Ambulatory Sleep Medicine Centers (HLAFABAJ)
- akta.pro secondary industries
- Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy) (HLAHAGAB), Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)
Keywords
Where Ognomy Sleep is headquartered
LocationHeadquarters
- HQ city
- Buffalo
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ognomy Sleep business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Telehealth Consultations: Revenue from virtual consultations with sleep medicine specialists. New patient appointments are $124, with follow-up appointments at $99 each. Most patients use insurance (Medicare and major insurance plans accepted) with typical copays of $25-$70 for sleep tests.
- Home Sleep Testing: At-home sleep study kits and interpretation services. Insurance-covered or self-pay at approximately $320 total package including initial consultation, home sleep test, and follow-up consultation.
- CPAP and Therapy Devices: Revenue from CPAP machines, masks, and accessories through Resmed partnership. Oral appliances and Inspire implant therapy coordination services.
- Zepbound Prescriptions: Prescription medication for sleep apnea treatment (Zepbound/tirzepatide) as part of comprehensive weight management program for adults with obesity and moderate-to-severe OSA.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Insurance-covered care with typical patient responsibility of $25-$70 for sleep tests |
| One time/ perpetual license | Pay-as-you-go | Self-pay complete package at $320 total |
| Other | Pay-as-you-go | No-show fees for missed appointments |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Ognomy Sleep product offering
Product offeringCore offering
Ognomy Sleep is a virtual sleep apnea care company that diagnoses and treats obstructive sleep apnea entirely through telehealth. Patients consult board-certified sleep medicine physicians via HIPAA-compliant video, are evaluated using FDA-cleared home sleep testing devices (with Oura Ring data supported), and are then treated with PAP therapy, custom oral appliances, Inspire hypoglossal nerve stimulation, and/or Zepbound weight-loss prescriptions as clinically indicated. The service is in-network with major U.S. payers and licensed in all 50 states.
Product overview
Ognomy Sleep is a virtual sleep apnea care platform offering end-to-end remote diagnosis and treatment. The core platform connects patients with sleep medicine specialists via telehealth consultations, supported by multiple FDA-cleared home sleep testing devices (WatchPAT, ApneaLink Air, SleepImage Ring, EnsoData, NightOwl). Treatment options include CPAP therapy through Resmed partnership, oral appliance therapy, Inspire implant therapy for CPAP-intolerant patients, and Zepbound (tirzepatide) prescriptions for weight management in OSA. The platform integrates with OURA Ring for wearables data, Resmed CPAP devices for therapy monitoring, and LillyDirect for prescription fulfillment. Patients access services through the mobile app or website, with a 90-second sleep apnea quiz as the entry point.
Differentiator
Problem solved
Functional benefit
Products and services
- Ognomy Virtual Sleep Apnea Care End-to-end virtual care pathway for obstructive sleep apnea covering online screening, specialist telehealth consultation, home sleep testing, treatment selection, and ongoing therapy management; available in all 50 U.S. states and in-network with major payers covering 200M+ lives.
- Home Sleep Apnea Testing Multi-device at-home sleep study service using FDA-cleared HSAT devices (WatchPAT, ApneaLink Air, SleepImage, Ectosense/NightOwl), with optional ingestion of biometric signals from the Oura Ring; ordered by Ognomy sleep medicine physicians and shipped to the patient's home.
- Sleep Medicine Telehealth Consultation HIPAA-compliant video consultation with a board-certified sleep medicine specialist for evaluation of suspected obstructive sleep apnea, treatment recommendation, and follow-up management.
- PAP (CPAP/BiPAP) Therapy Program Continuous and bilevel positive airway pressure therapy program for OSA, including device selection, Resmed myAir/Pathway integration for setup and adherence tracking, and ongoing coaching; Ognomy reports a 74% compliance rate versus the ~45% industry average.
- Oral Appliance Therapy Custom-fitted mandibular advancement oral appliances provided as an alternative to PAP for obstructive sleep apnea patients, prescribed and managed by Ognomy sleep medicine physicians.
- Inspire Hypoglossal Nerve Stimulation Therapy Inspire implant therapy program for OSA patients who are intolerant of or refractory to PAP, delivered in partnership with Inspire Medical Systems as a strategic investor and channel partner.
- Zepbound (tirzepatide) Weight-Loss Prescription Program Sleep medicine-led weight-loss prescribing service offering Zepbound (tirzepatide) for OSA patients with comorbid obesity, delivered through Ognomy's integration with the LillyDirect online pharmacy marketplace on a tiered monthly subscription.
Quantifiable outcome
- 74% regular CPAP use among Ognomy patients vs 45% standard average
- +3 more outcomes
Companies that use Ognomy Sleep
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Ognomy Sleep technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature3 records
Ognomy Sleep partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Eli Lilly & CompanycoreOgnomy Sleep is listed as an independent telehealth provider for sleep apnea care on Eli Lilly's LillyDirect platform. Ognomy patients may be prescribed Zepbound (tirzepatide), the FDA-approved GLP-1 medication for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
- ResmedcoreOgnomy partners with Resmed and other CPAP device makers to provide patients access to modern CPAP machines with high personalization. Ognomy is part of Resmed's Pathway program, allowing Resmed device users to access virtual sleep apnea care on the Ognomy platform.
- SleepopolisminorSleep apnea education content partnership featuring Ognomy in articles about sleep positions for sleep apnea and other sleep health topics.
- Fox NewsminorMedia coverage featuring Ognomy in health-related articles on topics like sleepwalking and sleep apnea awareness.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Ognomy Sleep competitors and assessment
Company assessmentDirect peers
- Lofta: Direct-to-consumer home sleep apnea testing and treatment platform offering at-home sleep studies and CPAP equipment. Closely comparable business model to Ognomy, with similar patient self-referral, home testing, and therapy fulfillment flow, but without the same integrated telehealth specialist layer across all 50 states.
- BetterNight: Virtual sleep care platform offering telehealth sleep consultations, home sleep testing, and CPAP therapy. Comparable end-to-end virtual sleep care model targeting similar patient segments, with both DTC and provider referral channels.
Broad incumbents
- AdaptHealth: Large national durable medical equipment (DME) provider with a strong CPAP and home respiratory therapy business. Comparable because it serves the same OSA patient population through home-delivered CPAP equipment and supplies, though via a traditional DME model rather than a fully integrated virtual specialist platform.
- Rotech Healthcare: National home medical equipment company with significant respiratory and sleep therapy (CPAP/BiPAP) business. Comparable in treating OSA patients via home-delivered CPAP, but as a traditional DME operator rather than a virtual specialist network.
- Apria Healthcare (Owens & Minor): Major home medical equipment provider, now part of Owens & Minor, with a large CPAP and sleep therapy portfolio. Comparable in serving OSA patients with home-delivered equipment and supplies, though through a more traditional, less virtual-first model.
- Resmed: Global leader in CPAP devices and digital sleep health (myAir app, Pathway program). Comparable as both an incumbent device maker and now a care delivery ecosystem player; Resmed is also an Ognomy partner, making it both competitor and collaborator.
- Inspire Medical Systems: Medical device company behind Inspire hypoglossal nerve stimulation therapy for OSA and an equity investor in Ognomy. Comparable as an OSA treatment provider, especially for CPAP-intolerant patients, and serves as both partner and adjacent incumbent.
- Lincare: Large US provider of home respiratory therapy, including CPAP and home sleep testing services. Comparable in delivering OSA equipment and clinical support to patients in the home, but operating primarily through a traditional DME model.
Emerging players
- Hims & Hers Health: Large direct-to-consumer telehealth platform expanding into sleep and weight loss categories. Comparable in using a national telehealth, D2C, and subscription model, though sleep apnea care is a newer, partial extension of its broader men's and women's health offering.
Others
- Itamar Medical (WatchPAT / ZOLL Itamar): Maker of the WatchPAT home sleep testing device, one of the FDA-cleared HST devices integrated into the Ognomy platform. Comparable as an enabling technology supplier in the OSA diagnostic chain, but not a direct competitor in care delivery.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Ognomy Sleep social profiles
Digital presenceOgnomy Sleep compliance and trust
Trust signalCompliance2 records
Ognomy Sleep financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ognomy Sleep leadership team
Management profileNumber of profiles
Profiles9 records
Ognomy Sleep funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ognomy Sleep M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ognomy Sleep
What does Ognomy Sleep do?
Ognomy Sleep is a virtual sleep apnea care company that diagnoses and treats obstructive sleep apnea entirely through telehealth. Patients consult board-certified sleep medicine physicians via HIPAA-compliant video, are evaluated using FDA-cleared home sleep testing devices (with Oura Ring data supported), and are then treated with PAP therapy, custom oral appliances, Inspire hypoglossal nerve stimulation, and/or Zepbound weight-loss prescriptions as clinically indicated. The service is in-network with major U.S. payers and licensed in all 50 states.
Is Ognomy Sleep a public or private company?
Ognomy Sleep is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ognomy Sleep founded?
Ognomy Sleep was founded in 2019. It employs 11 to 50 people.
Where is Ognomy Sleep based?
Ognomy Sleep is headquartered in Buffalo, United States, in the North America region.
How does Ognomy Sleep make money?
Four revenue lines are on record. Telehealth Consultations are the primary driver. The others are home Sleep Testing, CPAP and Therapy Devices and zepbound Prescriptions.
Who are Ognomy Sleep's main competitors?
Direct peers on record are Lofta and BetterNight. Broad incumbents are AdaptHealth, Rotech Healthcare, Apria Healthcare (Owens & Minor), Resmed, Inspire Medical Systems and Lincare. Hims & Hers Health is listed as an emerging player. Itamar Medical (WatchPAT / ZOLL Itamar) is listed as an others.
Does Ognomy Sleep have an API?
No public API is recorded for Ognomy Sleep.
What industry is Ognomy Sleep in?
Ognomy Sleep's product category is Telehealth Sleep Medicine. Its primary akta.pro industry code is HLAFABAJ, Ambulatory Sleep Medicine Centers, with a secondary code of HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy). Its NAICS code is 6211 and its SIC code is 8011.